{"id":"NCT03474679","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)","officialTitle":"A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-01","primaryCompletion":"2021-11-29","completion":"2021-11-29","firstPosted":"2018-03-22","resultsPosted":"2023-02-03","lastUpdate":"2025-02-04"},"enrollment":19,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Graft vs Host Disease"],"interventions":[{"type":"DRUG","name":"Ibrutinib","otherNames":["PCI-32765","JNJ-54179060"]}],"arms":[{"label":"Ibrutinib","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response \\[CR\\] and partial response \\[PR\\] defined by National Institutes of Health \\[NIH\\] consensus development project criteria \\[2014\\]).","primaryOutcome":{"measure":"Overall Response Rate (ORR)","timeFrame":"Up to 3 year 6 months","effectByArm":[{"arm":"Ibrutinib 420 mg","deltaMin":84.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":15,"countries":["Japan"]},"refs":{"pmids":["38149026","34102349"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":19},"commonTop":["Stomatitis","Cellulitis","Upper Respiratory Tract Infection","Platelet Count Decreased","Nausea"]}}